Ping Wu

University of Electronic Science and Technology of China — China

Medicine · Health Sciences

11h-index441citations62works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(27), Myeloproliferative Neoplasms: Diagnosis and Treatment(8), Histone Deacetylase Inhibitors Research(6), Hepatitis C virus research(5), Hepatitis B Virus Studies(5)

Publications62 total

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial
Trials·2025Open Access
Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial
Blood·2025Open Access
WITHDRAWN: 1184P Surgical outcomes in advanced gastric-type cervical adenocarcinoma: Multicenter evidence for survival benefits
Annals of Oncology·2025
Low prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma
Frontiers in Nutrition·2025· 2 citedOpen Access
MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center
Blood·2024Open Access
Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group
Blood·2024Open Access
Acute Pancreatitis and Leukemoid Reaction as the Presenting Manifestation of Hemorrhagic Fever with Renal Syndrome: A Case Report
Infection and Drug Resistance·2024· 1 citedOpen Access
Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
Clinical and Translational Science·2023· 1 citedOpen Access
Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML
Blood·2023· 1 citedOpen Access
Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia
Blood·2023
ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China
Blood·2023· 1 cited
Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center
Blood·2023Open Access
Development of rapid visual detection technology for Nosema bombycis based on CRISPR/Cas12a system
Entomologia Generalis·2023· 6 cited
Abstract 4845: Ultra-deep sequencing of mitochondrial genome to explore the dynamic mutational changes associated with oral cavity squamous cell carcinoma progression
Cancer Research·2023
Features of peritoneal dendritic cells in the development of endometriosis
Reproductive Biology and Endocrinology·2023· 19 citedOpen Access
3055 – MULTI-OMICS REVEALS AZACITIDINE PARTIALLY RESTORES THE HEMATOPOIESIS-SUPPORTIVE FUNCTIONS IN MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
Experimental Hematology·2023Open Access
Correlation of temperament characteristics and early functional exercise compliance in school-age children with limb fractures: Implication for clinical nursing care
Medicine·2022· 1 citedOpen Access
APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma
Heliyon·2022· 11 citedOpen Access
Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
Frontiers in Immunology·2022· 8 citedOpen Access
[Retracted] Characterization of the Prognostic Values of CXCL Family in Epstein–Barr Virus Associated Gastric Cancer
Oxidative Medicine and Cellular Longevity·2022· 9 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Suxia Geng(23), Jianyu Weng(23), Chengxin Deng(20), Xin Du(19), Minming Li(17), Peilong Lai(16), Zesheng Lu(13), Xin Huang(13), Ruohao Xu(9), Chengwei Luo(5), Lingji Zeng(5), Xiaomei Chen(5), Warren N. Schmidt(3), Douglas R. LaBrecque(3), Jack T. Stapleton(3), Yangqiu Li(3), Lisi Huang(3), Suijing Wu(3), Qihui Sun(2), Chenxin Deng(2)